MedPath

A randomized, single-blind, parallel-group, multi-center comparative study to assess the efficacy and safety of an application of Fybex (fibrin sealant) to the operative field, for the reduction of post-operative blood loss, when added to standard intra-operative hemostatic procedures and compared to standard intra-operative hemostatic procedures alone, in adult patients undergoing total hip arthroplasty - A study to assess the effect of Fybex fibrin sealant on post-operative blood loss, given during hip

Conditions
Total hip arthroplasty
Registration Number
EUCTR2005-001228-35-GB
Lead Sponsor
Bio Products Laboratory
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Authorised-recruitment may be ongoing or finished
Sex
All
Target Recruitment
90
Inclusion Criteria

·Patients undergoing total hip replacement·Age > 18 years·Able to give informed consent
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

·History of bleeding disorders·Hb < 110g/L·Previous hip surgery·Use of other blood products within 3 months·Positive for HBsAg, HCV or HIV

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Main Objective: To investigate the efficacy of Fybex in reducing post-operative blood loss in patients undergoing total hip arthroplasty.;Secondary Objective: To investigate the hemostatic effect and safety, including local tolerance and viral safety, of Fybex in patients undergoing total hip arthroplasty;Primary end point(s): Post-operative blood loss.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath